New drug cocktail aims to halt aggressive breast cancer
NCT ID NCT07359404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, sacituzumab govitecan and bevacizumab, in people with metastatic triple-negative breast cancer that has progressed after at least one prior treatment. The trial will enroll 60 participants across several centers in China. Researchers will first find the safest dose, then measure how long the cancer stays under control and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab Govitecan and Bevacizumab
What this could lead to
If successful, this combination could offer a new second-line or later treatment option for people with metastatic triple-negative breast cancer, potentially slowing disease progression.
What could go wrong
This is an early Phase II study with only 60 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China